Cardiomyopathy, Hypertrophic

The disease is commonly linked to gene mutations, with MYBPC3 highlighted as a major contributor in the supplied literature. The grounding also identifies familial hypertrophic cardiomyopathy as a genetic risk context. In addition, the literature notes that disease expression reflects an interplay between genetic mutation and environmental factors.

The core abnormality is myocardial hypertrophy with frequent septal predominance, which is associated with altered left ventricular function and reduced stroke volume. The literature also links cardiomyopathy manifestations to myocardial fibrosis and reduced contractility, and notes that arrhythmias may arise in this setting. Molecularly, disturbances in protein and transcript quality control systems, including the ubiquitin-proteasome system and nonsense-mediated RNA dysfunction, are implicated in MYBPC3-related disease.

The supplied MeSH definition identifies hypertension, aortic stenosis, and gene mutation as risk factors. Familial hypertrophic cardiomyopathy is also listed as a genetic risk context. The review literature further supports inherited disease predisposition, particularly in autosomal dominant forms.

Current management includes lifestyle optimisation, medications, septal reduction therapies, and, rarely, cardiac transplantation. The literature also emphasizes antiarrhythmic therapy and risk stratification because arrhythmias are common and clinically important. Diagnostic and treatment planning increasingly rely on multimodal imaging and phenotype-based assessment.